MBX Biosciences, Inc. (MBX)

MBX Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	12.84	10.98	6.98	3.86
Research & Development	68.57	57.22	28.33	21.3
Operating Expenses	81.41	68.19	35.31	25.16
Operating Income	-81.41	-68.19	-35.31	-25.16
Interest Expense	-	-	-	-0.37
Interest & Investment Income	5.02	3.34	1.7	0.35
Other Non Operating Income (Expenses)	-	-	-	-0.07
EBT Excluding Unusual Items	-76.39	-64.85	-33.61	-25.26
Gain (Loss) on Sale of Investments	2.93	2.93	1.04	0.03
Other Unusual Items	-	-	-	-0.9
Pretax Income	-73.47	-61.92	-32.56	-26.14
Net Income	-73.47	-61.92	-32.56	-26.14
Net Income to Common	-73.47	-61.92	-32.56	-26.14
Shares Outstanding (Basic)	19	11	1	1
Shares Outstanding (Diluted)	19	11	1	1
Shares Change (YoY)	1591.64%	944.70%	52.73%	-
EPS (Basic)	-3.93	-5.82	-31.96	-39.18
EPS (Diluted)	-3.93	-5.82	-31.96	-39.18
Free Cash Flow	-67.28	-55.56	-32.11	-23.56
Free Cash Flow Per Share	-3.60	-5.22	-31.52	-35.33
EBITDA	-81.14	-67.95	-35.15	-25.11
D&A For EBITDA	0.27	0.24	0.16	0.06
EBIT	-81.41	-68.19	-35.31	-25.16

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q